Soleno Therapeutics Inc Revenue Growth Rates (SLNO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Soleno Therapeutics Inc  (NASDAQ: SLNO)
 

SLNO's Revenue Growth by Quarter and Year

Soleno Therapeutics Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SLNO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 94.60
FY 94.60





SLNO Revenue first quarter 2026 Y/Y Growth Comment
Soleno Therapeutics Inc in the first quarter 2026 achieved Revenue of $ 94.60 millions compare to recorded in same quarter a year ago.

According to the results reported in the first quarter 2026, Soleno Therapeutics Inc achieved the best Revenue growth in Medical Equipment & Supplies industry. While Soleno Therapeutics Inc' s Revenue no change of 0% ranks overall at the positon no. in the first quarter 2026.


SLNO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Soleno Therapeutics Inc's first quarter 2026 Revenue $ 94.60 millions SLNO's Income Statement
Soleno Therapeutics Inc's first quarter 2025 Revenue $ 0.00 millions Quarterly SLNO's Income Statement


SLNO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 38.94 % - -
3rd Quarter September - 102.14 % - -
2nd Quarter June - - - -
1st Quarter March 3.13 % - - -
FY (Year on Year)   - - - -


Back to SLNO Growth rate Comparisons >> Back to SLNO Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Jun 30 2015)   (Sep 30 2017)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Jun 30 2015)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Soleno Therapeutics Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
340.91 % 36.48 % -100 %
(Jun 30 2015)  


SLNO's I. Quarter Q/Q Revenue Comment
Soleno Therapeutics Inc achieved in the I. Quarter 2026 below company average Revenue growth of 3.13% quarter on quarter, to $ 94.60 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the % in the I. Quarter a year ago.

Within Medical Equipment & Supplies industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Soleno Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 1109.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #39
Healthcare Sector #150
Overall #1109
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #39
Healthcare Sector #150
Overall #1109
Revenue Q/Q Growth Statistics
High Average Low
340.91 % 36.48 % -100 %
(Jun 30 2015)  


SLNO's I. Quarter Q/Q Revenue Comment
Soleno Therapeutics Inc achieved in the I. Quarter 2026 below company average Revenue growth of 3.13% quarter on quarter, to $ 94.60 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the % in the I. Quarter a year ago.

Within Medical Equipment & Supplies industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Soleno Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 1109.


Soleno Therapeutics Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 285.01 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment


Soleno Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment


Soleno Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SLNO's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Soleno Therapeutics Inc Revenue Growth Rates (SLNO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Soleno Therapeutics Inc (CIK 1484565).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-212205
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Soleno Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.